THiogenesiS
THerapeutics

Company Overview

(Sept. 2025 – C$'s)

Shares Issued: 51.8m *Market Cap. $39.4m*

Fully Dilluted: 55.8m

Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company focused on developing a novel class of thiol-based prodrugs aimed at reducing oxidative stress and restoring mitochondrial function. These processes are central to addressing inherited mitochondrial diseases such as MELAS and Leigh syndrome spectrum - conditions which originate from genetic mutations in either cellular or mitochondrial DNA - disrupting the cell's energy system and contributing to progressive, multisystem decline.

Beyond these rare inherited disorders, mitochondrial dysfunction also plays a role in acquired diseases, including metabolic diseases like pediatric Metabolic dysfunction-associated steatohepatitis (MASH) and certain neurological conditions.



About TTI-0102

The company's lead candidate, *TTI-0102*, is a third-generation prodrug of the thiol cysteamine. It is engineered to overcome the challenges that have historically limited thiol-based therapies, including poor tolerability, short half-life, and dose-limiting gastrointestinal side effects.

TTI-0102 is designed to generate cysteamine gradually and efficiently, increasing intracellular cysteine, a precursor to glutathione (GSH) - the body's master antioxidant - and taurine, which also contributes to mitochondrial stability. GSH is one of the few antioxidants that crosses the inner mitochondria, where it neutralizes reactive oxygen

species (free radicals), supports redox balance, and promotes cellular resilience to restore mitochondrial function.

In a healthy volunteer study, *TTI-0102* was well tolerated at doses up to four times higher than existing cysteamine therapies. Its pharmacokinetic profile suggests the potential for once-daily dosing and broader tissue distribution. Patent protection has been granted in the U.S. and Europe.

Regulatory

As a prodrug of a previously approved molecule, *TTI-0102* qualifies for the 505(b)(2) regulatory pathway in the U.S. and hybrid routes in Europe, enabling a faster and more cost-efficient development strategy.

The company is currently:

- Conducting a Phase 2 trial in MELAS at clinical sites in the EU
- Initiating a Phase 2a trial in the U.S. for Leigh syndrome spectrum (IND cleared)
- Planning additional Phase 2 trials in pediatric MASH

With a scalable drug platform, strong scientific foundation, and upcoming clinical milestones, Thiogenesis is positioned to deliver meaningful advances in the treatment of mitochondrial and metabolic diseases.

Forward Looking Statement

This document contains certain forward-looking statements and forward-looking information within the meaning of Canadian and U.S. securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur.